CD274 and neoplasm: ICIs target anti-programmed cell death receptor 1 (PD-1) and programmed cell death receptor ligand 1 (PD-L1), alleviating anti-tumor immunity suppression thereby enhancing the body’s ability to fight cancer [20, 21].